156 related articles for article (PubMed ID: 8410973)
21. A symmetric inhibitor binds HIV-1 protease asymmetrically.
Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
[TBL] [Abstract][Full Text] [Related]
22. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of potent macrocyclic renin inhibitors.
Sund C; Belda O; Wiktelius D; Sahlberg C; Vrang L; Sedig S; Hamelink E; Henderson I; Agback T; Jansson K; Borkakoti N; Derbyshire D; Eneroth A; Samuelsson B
Bioorg Med Chem Lett; 2011 Jan; 21(1):358-62. PubMed ID: 21112780
[TBL] [Abstract][Full Text] [Related]
24. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds.
Weber J; Majer P; Litera J; Urban J; Soucek M; Vondrásek J; Konvalinka J; Novek P; Sedlácek J; Strop P; Kräusslich HG; Pichová I
Arch Biochem Biophys; 1997 May; 341(1):62-9. PubMed ID: 9143353
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
Le VD; Mak CC; Lin YC; Elder JH; Wong CH
Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
[TBL] [Abstract][Full Text] [Related]
27. Engineering the substrate specificity of rhizopuspepsin: the role of Asp 77 of fungal aspartic proteinases in facilitating the cleavage of oligopeptide substrates with lysine in P1.
Lowther WT; Majer P; Dunn BM
Protein Sci; 1995 Apr; 4(4):689-702. PubMed ID: 7613467
[TBL] [Abstract][Full Text] [Related]
28. Novel renin inhibitors containing (2S,3S,5S)-2-amino-1-cyclohexyl-6-methyl-3,5-heptanediol fragment as a transition-state mimic at the P1-P1' cleavage site.
Yamada Y; Ando K; Ikemoto Y; Tada H; Shirakawa E; Inagaki E; Shibata S; Nakamura I; Hayashi Y; Ikegami K; Uchida I
Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1631-41. PubMed ID: 9353891
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of aspartic proteinases by propart peptides of human procathepsin D and chicken pepsinogen.
Fusek M; Mares M; Vágner J; Voburka Z; Baudys M
FEBS Lett; 1991 Aug; 287(1-2):160-2. PubMed ID: 1879525
[TBL] [Abstract][Full Text] [Related]
30. Substrate specificity of porcine renin: P1', P1, and P3 residues of renin substrates are crucial for activity.
Wang W; Liang TC
Biochemistry; 1994 Dec; 33(48):14636-41. PubMed ID: 7981226
[TBL] [Abstract][Full Text] [Related]
31. Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond.
Kempf DJ; de Lara E; Stein HH; Cohen J; Plattner JJ
J Med Chem; 1987 Nov; 30(11):1978-83. PubMed ID: 3312604
[TBL] [Abstract][Full Text] [Related]
32. Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR.
Lamar J; Hu J; Bueno AB; Yang HC; Guo D; Copp JD; McGee J; Gitter B; Timm D; May P; McCarthy J; Chen SH
Bioorg Med Chem Lett; 2004 Jan; 14(1):239-43. PubMed ID: 14684335
[TBL] [Abstract][Full Text] [Related]
33. Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools.
Arnold D; Keilholz W; Schild H; Dumrese T; Stevanović S; Rammensee HG
Eur J Biochem; 1997 Oct; 249(1):171-9. PubMed ID: 9363769
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors.
Weber AE; Halgren TA; Doyle JJ; Lynch RJ; Siegl PK; Parsons WH; Greenlee WJ; Patchett AA
J Med Chem; 1991 Sep; 34(9):2692-701. PubMed ID: 1895289
[TBL] [Abstract][Full Text] [Related]
35. The potential of P1 site alterations in peptidomimetic protease inhibitors as suggested by virtual screening and explored by the use of C-C-coupling reagents.
Weik S; Luksch T; Evers A; Böttcher J; Sotriffer CA; Hasilik A; Löffler HG; Klebe G; Rademann J
ChemMedChem; 2006 Apr; 1(4):445-57. PubMed ID: 16892380
[TBL] [Abstract][Full Text] [Related]
36. New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.
Luly JR; Bolis G; BaMaung N; Soderquist J; Dellaria JF; Stein H; Cohen J; Perun TJ; Greer J; Plattner JJ
J Med Chem; 1988 Mar; 31(3):532-9. PubMed ID: 3279206
[TBL] [Abstract][Full Text] [Related]
37. X-ray analyses of aspartic proteinases. III Three-dimensional structure of endothiapepsin complexed with a transition-state isostere inhibitor of renin at 1.6 A resolution.
Veerapandian B; Cooper JB; Sali A; Blundell TL
J Mol Biol; 1990 Dec; 216(4):1017-29. PubMed ID: 2266553
[TBL] [Abstract][Full Text] [Related]
38. Conformational flexibility of beta-secretase: molecular dynamics simulation and essential dynamics analysis.
Xiong B; Huang XQ; Shen LL; Shen JH; Luo XM; Shen X; Jiang HL; Chen KX
Acta Pharmacol Sin; 2004 Jun; 25(6):705-13. PubMed ID: 15169620
[TBL] [Abstract][Full Text] [Related]
39. Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements.
Raddatz P; Minck KO; Rippmann F; Schmitges CJ
J Med Chem; 1994 Feb; 37(4):486-97. PubMed ID: 8120867
[TBL] [Abstract][Full Text] [Related]
40. Substrate specificities of pepstatin-insensitive carboxyl proteinases from gram-negative bacteria.
Ito M; Dunn BM; Oda K
J Biochem; 1996 Oct; 120(4):845-50. PubMed ID: 8947851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
